My Green Doctor
MAY 3, 2025
A 2010 research study found that treating two patients per bottle instead of one would decrease plastic waste by approximately 12.69 operating rooms is regulated by the individual states; changing to multi-dose eyedrops will require administrative and legislative advocacy by eye specialists in every state and country. 3 “Each U.S.
FDA Law Blog
NOVEMBER 1, 2023
Regulating LDTs: A Long and Winding Road In what might sound to some like protesting too much, the PR invokes FDA’s longstanding assertion that IVDs “manufactured” by laboratories are medical devices and that clinical laboratories that develop tests are acting as manufacturers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
My Green Doctor
MAY 3, 2025
A 2010 research study found that treating two patients per bottle instead of one would decrease plastic waste by approximately 12.69 operating rooms is regulated by the individual states; changing to multi-dose eyedrops will require administrative and legislative advocacy by eye specialists in every state and country. 3 “Each U.S.
FDA Law Blog
OCTOBER 24, 2024
Gibbs — A recent blog post focused on the potentially negative implications of the proposed Patent Eligibility Restoration Act (PERA) for manufacturers of generic drugs and biosimilar products. By 2010, about 2000 isolated human genes had been patented in the U.S. Javitt & Jeffrey N.
Expert insights. Personalized for you.
52 
Let's personalize your content